| Overview: | Daiichi Sankyo, Inc., (DSI) is the U.S. headquarters of Tokyo-based DAIICHI SANKYO, COMPANY, LTD. DSI is a member of the Daiichi Sankyo Group, which spans 56 countries. Click here to download an easy-to-read company overview. |
| Established: | DSI was established in 2006 from the merger of the Daiichi and Sankyo pharmaceutical companies. |
| Industry: | Pharmaceuticals |
| Concentration: | Cardiovascular and metabolics therapies including a wide range of treatments for hypertension and heart disease, diabetes and hyperlipidemia. |
| U.S. Headquarters: | Daiichi Sankyo, Inc.
Two Hilton Court
Parsippany, NJ 07054
Phone: 973-944-2600 |
| President and CEO: | John P. Gargiulo |
| U.S. Employees: | Approximately 3,000 including Daiichi Sankyo Pharma Development |
| FY 2010 Net Sales: | $1.522 billion (in North America including Ranbaxy and Luitpold) |
| FY 2010 Global R&D Expenses: | 20.1% (against net sales) |
| Global Clinical Development: | Daiichi Sankyo Pharma Development
399 Thornall Street
Edison, NJ 08837
Phone: 732-590-5000 |
| Global Head of Development/President | Glenn J. Gormley, M.D., Ph.D.
Also Chief Science Officer/Co-Head of R&D at Daiichi Sankyo |
| Parent Company: | DAIICHI SANKYO, COMPANY, LTD. (TSE 4568)
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo
103-8426, Japan
Phone: +81-3-6225-1111
daiichisankyo.com |
| European Headquarters: | DAIICHI SANKYO EUROPE, GhbH
Zielstattstrasse 48
81379 Munich, Germany
Phone: +49-89-7808-0
daiichi-sankyo.eu |
| Employees Worldwide: | 29,272 (consolidated as of 7/2010) |
| Products Marketed in the U.S.: | AZOR® (amlodipine/olmesartan medoxomil)
See full Prescribing Information including boxed warning regarding avoiding use during Pregnancy.
BENICAR® (olmesartan medoxomil)
See full Prescribing Information including boxed warning regarding avoiding use during Pregnancy.
BENICAR HCT® (olmesartan medoxomil/hydrocholorothiazide)
See full Prescribing Information including boxed warning regarding avoiding use during Pregnancy.
EFFIENT® (prasugrel) tablets
See full Prescribing Information including boxed warning regarding Bleeding Risk.
EVOXAC® (cevimeline HCI)
See full Prescribing Information.
SPRIX® (ketorolac tromethamine) Nasal Spray
See accompanying complete Prescribing Information, including Boxed Warning.
TRIBENZOR™
(olmesartan medoxomil/amlodipine/hydrocholorothiazide)
See full Prescribing Information including boxed warning regarding avoiding use during Pregnancy.
WELCHOL® (colesevelam HCI)
See full Prescribing Information.
ZELBORAF™ (vemurafenib)
See full Prescribing Information.
|
